|
1
|
Kuebler JP, Wieand HS, O'Connell MJ, et
al: Oxaliplatin combined with weekly bolus fluorouracil and
leucovorin as surgical adjuvant chemotherapy for stage II and III
colon cancer: results from NSABP C-07. J Clin Oncol. 25:2198–2204.
2007. View Article : Google Scholar
|
|
2
|
Chen LT and Whang-Peng J: Current status
of clinical studies for colorectal cancer in Taiwan. Clin
Colorectal Cancer. 4:196–203. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Gramont AD, Tournigand C, André T,
Larsen AK and Louvet C: Adjuvant therapy for stage II and III
colorectal cancer. Semin Oncol. 34(Suppl 1): S37–S40. 2007.
|
|
4
|
Schippinger W, Samonigg H, Schaberl-Moser
R, et al: A prospective randomised phase III trial of adjuvant
chemotherapy with 5-fluorouracil and leucovorin in patients with
stage II colon cancer. Br J Cancer. 97:1021–1027. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gonzalez-Haba E, García MI, Cortejoso L,
et al: ABCB1 gene polymorphisms are associated with adverse
reactions in fluoropyrimidine-treated colorectal cancer patients.
Pharmacogenomics. 11:1715–1723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Casado E, De Castro J, Belda-Iniesta C, et
al: Molecular markers in colorectal cancer: genetic bases for a
customised treatment. Clin Transl Oncol. 9:549–554. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Perez RP, Hamilton TC and Ozols RF:
Resistance to alkylating agents and cisplatin: insights from
ovarian carcinoma model systems. Pharmacol Ther. 48:19–27. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
El-akawi Z, Abu-hadid M, Perez R, et al:
Altered glutathione metabolism in oxaliplatin resistant ovarian
carcinoma cells. Cancer Lett. 105:5–14. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Theile D, Grebhardt S, Haefeli WE and
Weiss J: Involvement of drug transporters in the synergistic action
of FOLFOX combination chemotherapy. Biochem Pharmacol.
78:1366–1373. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ballatori N, Hammond CL, Cunningham JB,
Krance SM and Marchan R: Molecular mechanisms of reduced
glutathione transport: role of the MRP/CFTR/ABCC and OATP/SLC21A
families of membrane proteins. Toxicol Appl Pharmacol. 204:238–255.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sun N, Sun X, Chen B, et al: MRP2 and
GSTP1 polymorphisms and chemotherapy response in advanced non-small
cell lung cancer. Cancer Chemother Pharmacol. 65:437–446. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nies AT and Keppler D: The apical
conjugate efflux pump ABCC2 (MRP2). Pflugers Arch. 453:643–659.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Meyer zu Schwabedissen HE, Jedlitschky G,
Gratz M, et al: Variable expression of MRP2 (ABCC2) in human
placenta: influence of gestational age and cellular
differentiation. Drug Metab Dispos. 33:896–904. 2005.PubMed/NCBI
|
|
14
|
Kroetz DL, Liu W, Nguyen TD, et al:
1249G>A polymorphism of ABCC2 (MRP2) is associated with
altered gene expression in human liver. J Clin Oncol. 24(Suppl):
130722006.
|
|
15
|
Toh S, Wada M, Uchiumi T, et al: Genomic
structure of the canalicular multispecific organic
anion-transporter gene (MRP2/cMOAT) and mutations in the
ATP-binding-cassette region in Dubin-Johnson syndrome. Am J Hum
Genet. 64:739–746. 1999. View
Article : Google Scholar
|
|
16
|
Choi JH, Ahn BM, Yi J, et al: MRP2
haplotypes confer differential susceptibility to toxic liver
injury. Pharmacogenet Genomics. 17:403–415. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Naesens M, Kuypers DR, Verbeke K and
Vanrenterghem Y: Multidrug resistance protein 2 genetic
polymorphisms influence mycophenolic acid exposure in renal
allograft recipients. Transplantation. 82:1074–1084. 2006.
View Article : Google Scholar
|
|
18
|
Liedert B, Materna V, Schadendorf D,
Thomale J and Lage H: Overexpression of cMOAT (MRP2/ABCC2) is
associated with decreased formation of platinum-DNA adducts and
decreased G2-arrest in melanoma cells resistant to cisplatin. J
Invest Dermatol. 121:172–176. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shen DW, Goldenberg S, Pastan I and
Gottesman MM: Decreased accumulation of [14C]carboplatin in human
cisplatin-resistant cells results from reduced energy-dependent
uptake. J Cell Physiol. 183:108–116. 2000.
|
|
20
|
Petrova DT, Nedeva P, Maslyankov S, et al:
No association between MDR1 (ABCB1) 2677G>T and 3435C>T
polymorphism and sporadic colorectal cancer among Bulgarian
patients. J Cancer Res Clin Oncol. 134:317–322. 2008. View Article : Google Scholar
|
|
21
|
Nishioka C, Sakaeda T, Nakamura T, et al:
MDR1, MRP1 and MRP2 genotypes and in vitro chemosensitivity in
Japanese patients with colorectal adenocarcinomas. Kobe J Med Sci.
50:181–188. 2004.PubMed/NCBI
|
|
22
|
Xingsheng Y, Sekine M, Kurata H, et al:
Single nucleotide polymorphisms in MRP2 gene and their significance
on chemosensitivity of advanced ovarian cancer. J Pract Obstet
Gynecol. 20:153–155. 2004.
|
